Cover Image
市場調查報告書

增生性糖尿病視網膜病變(PDR):開發平台分析

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257829
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
增生性糖尿病視網膜病變(PDR):開發平台分析 Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 63 Pages
簡介

增生性糖尿病視網膜病變(PDR)是糖尿病中最嚴重的類型。風險因子有糖尿病,高血壓,高膽固醇值,妊娠,抽煙等。症狀有視野中出現黑點、飛蚊症、失明、視野晃動、視線朦朧、色彩辨視困難等。

本報告提供增生性糖尿病視網膜病變(PDR)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等訊息。

簡介

  • 調查範圍
  • 增生性糖尿病視網膜病變(PDR)概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

增生性糖尿病視網膜病變(PDR):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • OcuCure Therapeutics, Inc.
  • Sirnaomics, Inc.
  • Ohr Pharmaceutical Inc.
  • Icon Bioscience, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ATL-1103
  • cyclosporine
  • ocriplasmin (組換形式)
  • OLX-302
  • PAN-90806
  • RBM-008
  • squalamine lactate
  • STP-601

增生性糖尿病視網膜病變(PDR):最近的開發平台趨勢

增生性糖尿病視網膜病變(PDR):暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8509IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 4 and 1 respectively for Proliferative Diabetic Retinopathy (PDR).

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Proliferative Diabetic Retinopathy (PDR) Overview
  • Therapeutics Development
    • Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview
  • Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies
  • Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development
    • Acucela Inc.
    • Aerie Pharmaceuticals, Inc.
    • Antisense Therapeutics Limited
    • Icon Bioscience, Inc.
    • OcuCure Therapeutics, Inc.
    • Ohr Pharmaceutical Inc.
    • PanOptica, Inc.
    • Ribomic Inc.
    • ThromboGenics NV
  • Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-13154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atesidorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emixustat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OC-10X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocriplasmin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OLX-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAN-90806 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • squalamine lactate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Proliferative Diabetic Retinopathy (PDR) - Dormant Projects
  • Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones
    • Featured News & Press Releases
      • May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Limited, H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience, Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by OcuCure Therapeutics, Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by PanOptica, Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc., H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Pipeline by ThromboGenics NV, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top